Results 101 to 110 of about 44,651 (208)

Interferons in the treatment of myeloproliferative neoplasms

Therapeutic Advances in Hematology
Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years.
Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M. Palmer, Aaron T. Gerds, Lucia Masarova, Andrew T. Kuykendall, Raajit K. Rampal, Ruben Mesa, Srdan Verstovsek   +11 more
doaj   +1 more source

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study. [PDF]

Int J Infect Dis, 2021
Pandit A, Bhalani N, Bhushan BLS, Koradia P, Gargiya S, Bhomia V, Kansagra K.   +6 more
europepmc   +1 more source

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. [PDF]

Qual Life Res, 2023
McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI.   +17 more
europepmc   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

The comparative study of the effectiveness of BCG and Alfa-Interferon in preventing the recurrence of bladder tumor

مجله دانشگاه علوم پزشکی گرگان, 1999
In this study 32 patients whom had only one superficial bladder tumor (T?-T1 stage) were selected to investigate the effectiveness of either BCG of Alfa-Interferon in preventing the recurrence of tumor.
Ghazimoghadam B (MD), Jabalameli P (MD)
doaj  

Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. [PDF]

Lancet Haematol, 2022
Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA, Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams.   +8 more
europepmc   +1 more source

Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.

JAMA Netw Open, 2023
Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L, Li J, Sai K, Xi S, Ouyang H, Liu M, Li X, Li Z, Ni X, Cao X, Li C, Wu S, Du X, Su J, Xue X, Wang Y, Li G, Qin Z, Yang H, Zhou T, Liu J, Hu X, Wang J, Jiang X, Lin F, Zhang X, Ke C, Lv X, Lv Y, Hu W, Zeng J, Chen Z, Zhong S, Wang H, Chen Y, Zhang J, Li D, Mou Y, Chen Z.   +43 more
europepmc   +1 more source

The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size. [PDF]

Arq Bras Oftalmol, 2021
Vilaltella M, Huerva V.
europepmc   +1 more source

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature. [PDF]

Cancers (Basel), 2020
How J, Hobbs G.
europepmc   +1 more source

The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation. [PDF]

Cell Mol Gastroenterol Hepatol, 2021
Lee WJ, Jones M, Wing PAC, Rajagopal S, Foster GR.   +4 more
europepmc   +1 more source